Safer Use of Antipsychotics in Youth (SUAY)
Robert Penfold, PhD
|Principal Investigator Contact Information:|
|Principal Investigator institution:|
Kaiser Permanente Washington Health Research Institute
Base period: 04/25/16 – 12/24/16
Option period 1: 12/25/16-12/24/17
Option period 2: 12/25/17-06/24/2021
This study proposes to test a quality improvement research program. The project is inspired by the Partnership Access Line (PAL) and Second Opinion program operated for the Washington State Medicaid program. PAL was established to bring rapid child mental health consultation access into underserved areas of WA State. Under the program, a mandatory Second Opinion review protocol is triggered for new antipsychotics prescriptions when a set of pre-established criteria are met. SUAY is a step-wise research contract with 3 separately-funded phases: (1) planning and development, (2) feasibility pilot study at 2 sites, and (3) full-scale pragmatic effectiveness trial at 4 sites. The usual care arm is primarily observational only. The only change from standard usual care is a best practice alert reminding providers of Choosing Wisely® guidelines when prescribing antipsychotics for youth. The interventional arm consists of a more robust best practice alert informing prescribers that the case will be reviewed by a child and adolescent psychiatrist and offering a provider-to-provider consultation for the prescriber and behavioral health access support for the patient. Patients with an intervention arm prescriber will be offered 6 months of behavioral health navigation to support access and engagement with therapy in the health system and up to 9 sessions of brief telemental health (clinic-to-home) therapy to bridge wait times to access in-person therapy in the delivery system. Outcomes will be assessed at 6 months.
Kaiser Permanente Washington (KPWA)
Seattle Children’s Hospital (SCH)
Kaiser Permanente Colorado (KPCO)
Henry Ford Health System (HFHS) (base period and option period 1)
Kaiser Permanente Northwest (KPNW) (option period 2)
Nationwide Children’s Hospital (NCH) / Partners for Kids (PFK)
University of Washington (UW)
Robert Penfold, PhD – Kaiser Permanente Washington Health Research Institute
Greg Simon, MD, MPH – Kaiser Permanente Washington Health Research Institute
James Ralston, MD, MPH – Kaiser Permanente Washington Health Research Institute
Clarissa Hsu, PhD – Kaiser Permanente Washington Health Research Institute
Rebecca Yates Coley, PhD – Kaiser Permanente Washington Health Research Institute
Tobias Dang, MD – Kaiser Permanente Washington Behavioral Health Services
Robert Hilt, MD – Seattle Children’s Hospital
Kathleen Myers, MD – Seattle Children’s Hospital
Kelly Kelleher, MD – Nationwide Children’s Hospital (NCH) /Partners for Kids (PFK)
Brian Ahmedani, PhD – Henry Ford Health System (base period and option period 1)
Arne Beck, PhD – Kaiser Permanente Colorado
Bobbi Jo Yarborough, PhD – Kaiser Permanente Northwest
Andrea Hartzler, PhD – University of Washington (base period and option period 1)
Paul Fishman, PhD – University of Washington
Base period (8 months): Develop a treatment algorithm and step-by-step clinical workflow that aims to promote the safer use of antipsychotics in youth aged 3-17 years who do not have a psychotic disorder, mania, autism spectrum disorder, or intellectual disability. Base period activities include convening a consensus panel of national experts to develop the treatment algorithm; interviewing youth, parents, and prescriber clinicians; conducting user-centered design sessions with prescribing clinicians and psychiatrists; and preparing for an option period 1 pilot study. Option period 1 (12 months): Conduct a pilot study to test the feasibility, acceptability, reproducibility and implementation of the intervention and workflow in two health systems (up to 20 patients per clinical site). Kaiser Permanente Washington and Nationwide Children’s Hospital will participate in the pilot. Option period 2 (3 years, 6 months): Conduct a full-scale pragmatic effectiveness study comparing usual care to the interventional arm at four health systems (up to 800 patients enrolled across the 4 clinical sites). Kaiser Permanente Washington, Nationwide Children’s Hospital, Kaiser Permanente Northwest, and Kaiser Permanente Colorado will participate in the pragmatic trial.
|Description of study sample:|
Provider-subjects: The study will pre-randomize clinicians credentialed to prescribe medications in the health systems’ internal electronic medical record. Providers will be randomized to one of two arms: (1) usual care control and (2) intervention. Patient-subjects: Patients between the ages of 3 and 17 not ordered an outpatient antipsychotic in the health system during the prior 6 months and not suffering from a psychotic disorder, mania, autism spectrum disorder or intellectual disability. Patient subjects will be added to a study log when a randomized provider enters an antipsychotic medication order for them in Epic.
The pragmatic trial fielded at Kaiser Permanente Washington in March 2018, Kaiser Permanente Colorado in June 2018, and at Nationwide Children’s Hospital in July 2018. Henry Ford Health System was unable to field the protocol and the contract was modified to add Kaiser Permanente Northwest as a fourth recruitment site. Kaiser Permanente Northwest fielded the trial in May 2019. The end date of the contract may be extended to allow for a longer recruitment period given delays to fielding. The study had enrolled a total of 500 subjects as of July 1, 2019 (63% of the target 800 subjects).
The trial is registered in ClinicalTrials.gov under record number NCT03448575.
Hartzler A, Ralston J, Penfold R, Kelleher K, Hannan T. Designing safer use of antipsychotics in youth: A human centered approach. Accepted by Psychiatric Services for publication.Schoenfelder-Gonzalez E, Myers K, Thompson E, King D, Glass A, Penfold R. Developing Home-Based Telemental Health Services for Youth: Practices from the SUAY Study. Accepted by the Journal of Telemedicine and Telecare for publication.
|Resources: Clinical guidelines developed by a national panel of experts for the safer prescribing of antipsychotic prescribing in youth. EPIC build package. Study protocol and manual of procedures.|
Recruitment for the large pragmatic effectiveness study will continue into Spring 2020 and intervention delivery and follow-up through Fall 2020. Data and safety monitoring board reports will continue to be prepared and delivered three times per year.